Esther W Bouman-Wammes1, Joyce M van Dodewaard-De Jong2, Max Dahele3, Matthijs C F Cysouw4, Otto S Hoekstra4, R Jeroen A van Moorselaar5, Maartje A H Piet3, Hein J Verberne6, Adriaan D Bins7, Henk M W Verheul8, Ben J Slotman3, Daniela E Oprea-Lager4, Alfons J M Van den Eertwegh8. 1. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: e.bouman@vumc.nl. 2. Department of Medical Oncology, Meander Medical Center, Amersfoort, The Netherlands. 3. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands. 4. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands. 5. Department of Urology, VU University Medical Center, Amsterdam, The Netherlands. 6. Department of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands. 7. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands. 8. Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
INTRODUCTION: For patients with oligometastatic recurrence of prostate cancer (PC), stereotactic body radiation therapy (SBRT) represents an attractive treatment option, as it is safe without major side effects. The aim of this study was to investigate the impact of SBRT in delaying the start of androgen deprivation therapy (ADT). PATIENTS AND METHODS: Forty-three patients treated with SBRT for oligometastatic recurrence (< 5 metastases) of hormone-sensitive PC, defined with [18F]fluoromethylcholine positron emission tomography/computed tomography were included. As a control group, 20 patients with oligometastatic disease not treated with SBRT were identified from another hospital. Data were collected retrospectively. RESULTS: A post-SBRT prostate-specific antigen (PSA) response was seen in 29 (67.4%) of 43 patients. Median ADT-free survival (ADT-FS) was 15.6 months (95% confidence interval [CI], 11.7-19.5) for the whole group, and 25.7 months (95% CI, 9.0-42.4) for patients with a PSA response. Seven patients were treated with a second course of SBRT because of oligometastatic disease recurrence; the ADT-FS in this group was 32.1 months (95% CI, 7.8-56.5). Compared with the control group, the ADT-FS from first diagnosis of metastasis was significantly longer, with 17.3 (95% CI, 13.7-20.9) months versus 4.19 months (95% CI, 0.0-9.0), P < .001. Also, time between diagnosis of the metastasis until progression of disease during ADT use (castration resistance) was longer for the SBRT-treated patients (mean 66.6, 95% CI, 53.5-79.8, vs. 36.41, 95% CI, 26.0-46.8 months, P = .020). There were no grade III or IV adverse events reported. CONCLUSION: SBRT can safely and effectively be used to postpone ADT in appropriately selected patients with oligometastatic recurrence of PC.
INTRODUCTION: For patients with oligometastatic recurrence of prostate cancer (PC), stereotactic body radiation therapy (SBRT) represents an attractive treatment option, as it is safe without major side effects. The aim of this study was to investigate the impact of SBRT in delaying the start of androgen deprivation therapy (ADT). PATIENTS AND METHODS: Forty-three patients treated with SBRT for oligometastatic recurrence (< 5 metastases) of hormone-sensitive PC, defined with [18F]fluoromethylcholine positron emission tomography/computed tomography were included. As a control group, 20 patients with oligometastatic disease not treated with SBRT were identified from another hospital. Data were collected retrospectively. RESULTS: A post-SBRTprostate-specific antigen (PSA) response was seen in 29 (67.4%) of 43 patients. Median ADT-free survival (ADT-FS) was 15.6 months (95% confidence interval [CI], 11.7-19.5) for the whole group, and 25.7 months (95% CI, 9.0-42.4) for patients with a PSA response. Seven patients were treated with a second course of SBRT because of oligometastatic disease recurrence; the ADT-FS in this group was 32.1 months (95% CI, 7.8-56.5). Compared with the control group, the ADT-FS from first diagnosis of metastasis was significantly longer, with 17.3 (95% CI, 13.7-20.9) months versus 4.19 months (95% CI, 0.0-9.0), P < .001. Also, time between diagnosis of the metastasis until progression of disease during ADT use (castration resistance) was longer for the SBRT-treated patients (mean 66.6, 95% CI, 53.5-79.8, vs. 36.41, 95% CI, 26.0-46.8 months, P = .020). There were no grade III or IV adverse events reported. CONCLUSION:SBRT can safely and effectively be used to postpone ADT in appropriately selected patients with oligometastatic recurrence of PC.
Authors: Dennis Winkel; Anita M Werensteijn-Honingh; Petra S Kroon; Wietse S C Eppinga; Gijsbert H Bol; Martijn P W Intven; Hans C J de Boer; Louk M W Snoeren; Jochem Hes; Bas W Raaymakers; Ina M Jürgenliemk-Schulz Journal: Clin Transl Radiat Oncol Date: 2019-03-30
Authors: Paul Rogowski; Mack Roach; Nina-Sophie Schmidt-Hegemann; Christian Trapp; Rieke von Bestenbostel; Run Shi; Alexander Buchner; Christian Stief; Claus Belka; Minglun Li Journal: Radiat Oncol Date: 2021-03-09 Impact factor: 3.481
Authors: Goda Kalinauskaite; Carolin Senger; Anne Kluge; Christian Furth; Markus Kufeld; Ingeborg Tinhofer; Volker Budach; Marcus Beck; Alexandra Hochreiter; Arne Grün; Carmen Stromberger Journal: PLoS One Date: 2020-10-21 Impact factor: 3.240
Authors: Charlotte L Deijen; Gerbert L Vrijenhoek; Eva E Schaake; Wouter V Vogel; Luc M F Moonen; Floris J Pos; Henk G van der Poel; Gerben R Borst Journal: Clin Transl Radiat Oncol Date: 2021-06-29